TERSUS LIFE SCIENCES, LLC – Trademark Portfolio
Entity Type: 16
TERSUS LIFE SCIENCES, LLC holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 11 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 7 trademarks are registered. Notable registered marks include LIPPOA, CARDIA7, CARDIA 3, FLEXINOL, and PROVINAL. The owner is based in Bonita Springs, FL.
8000 Health Center Blvd., Ste. 100
Bonita Springs, FL 34135
Showing of trademarks Trademarks
Trademark Classifications
TERSUS LIFE SCIENCES, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does TERSUS LIFE SCIENCES, LLC have?
TERSUS LIFE SCIENCES, LLC has 12 U.S. trademarks filed with the USPTO. Of these, 7 registered, 1 abandoned, 4 cancelled.
What trademark classes does TERSUS LIFE SCIENCES, LLC file in?
TERSUS LIFE SCIENCES, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are TERSUS LIFE SCIENCES, LLC's most well-known trademarks?
TERSUS LIFE SCIENCES, LLC's registered trademark portfolio includes well-known marks such as LIPPOA, CARDIA7, CARDIA 3, FLEXINOL, and PROVINAL. These are among 7 currently registered trademarks in the portfolio.
What is TERSUS LIFE SCIENCES, LLC's trademark registration success rate?
TERSUS LIFE SCIENCES, LLC has a 58% trademark registration rate, with 7 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.